FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 828 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR ESMO contributes to discussions on the future of cancer care at EU Cancer Mission event Multicancer early detection test detects tumour-derived cfDNA and demonstrates robust performance characteristics with a favourable safety profile Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma MOST POPULAR “Hero” Nurses Plan Wedding In 24 Hours So Dying Patient Can... May 10, 2019 Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes July 16, 2020 Qué saber sobre los diferentes tipos de mastectomías para el cáncer... November 15, 2023 Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer? October 3, 2023 Load more HOT NEWS Cancer in My Community: Obstacles to Caring for People With Cancer... News digest – skin cancer deaths, Public Health England plans and... Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival Use of Immune Checkpoint Inhibitors is Safe and Effective in Patients...
